InvestorsHub Logo
Followers 275
Posts 35950
Boards Moderated 2
Alias Born 04/05/2012

Re: TheFinalCD post# 44

Thursday, 06/22/2017 6:04:08 AM

Thursday, June 22, 2017 6:04:08 AM

Post# of 1674
Novartis today announced topline results from the global Phase III CANTOS study investigating the efficacy, safety and tolerability of ACZ885 (canakinumab) in combination with standard of care in people with a prior heart attack and inflammatory atherosclerosis. With more than 10,000 patients enrolled in the study over the last six years, CANTOS is one of the largest and longest-running clinical trials in Novartis' history.

D1sclaimer: I am not a financial advisor or a stock promoter. I am an investor, Period! Do your own DD and make your own investment decisions.